| First Author | Kim K | Year | 2018 |
| Journal | Cell Metab | Volume | 27 |
| Issue | 4 | Pages | 816-827.e4 |
| PubMed ID | 29576536 | Mgi Jnum | J:263041 |
| Mgi Id | MGI:6157219 | Doi | 10.1016/j.cmet.2018.02.010 |
| Citation | Kim K, et al. (2018) gamma-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor. Cell Metab 27(4):816-827.e4 |
| abstractText | Excess plasma triglycerides (TGs) are a key component of obesity-induced metabolic syndrome. We have shown that gamma-secretase inhibitor (GSI) treatment improves glucose tolerance due to inhibition of hepatic Notch signaling but found additional Notch-independent reduction of plasma TG-rich lipoproteins (TRLs) in GSI-treated, as well as hepatocyte-specific, gamma-secretase knockout (L-Ncst) mice, which suggested a primary effect on hepatocyte TRL uptake. Indeed, we found increased VLDL and LDL particle uptake in L-Ncst hepatocytes and Ncst-deficient hepatoma cells, in part through reduced gamma-secretase-mediated low-density lipoprotein receptor (LDLR) cleavage and degradation. To exploit this novel finding, we generated a liver-selective Nicastrin ASO, which recapitulated glucose and lipid improvements of L-Ncst mice, with increased levels of hepatocyte LDLR. Collectively, these results identify the role of hepatic gamma-secretase to regulate LDLR and suggest that liver-specific GSIs may simultaneously improve multiple aspects of the metabolic syndrome. |
